Literature DB >> 3997302

Night-time pharmacokinetics of once a day theophylline: a steady state comparison of three preparations.

P Karttunen, H Tukiainen, S Nykänen, V Saano.   

Abstract

We have carried out a steady state pharmacokinetic comparison of three different theophylline preparations in nine healthy volunteers using a once a day dosage schedule of 600 mg theophylline given before bedtime for four days. The preparations tested were Retafyllin 200 mg depot tablet (R), Theo-Dur 200 mg depot tablet (T) and Uniphyllin 200 mg tablet (U). All preparations in steady state reached the serum level of 8.9-10.2 microg/ml after a single evening dose of theophylline 600 mg. The pharmacokinetic profile of these slow release theophylline preparations was such that there is no risk of exceeding the therapeutic range even after a rather high evening dose. Individual variation was also observed in the present study but nobody exceeded the therapeutic range. The pharmacokinetic profiles of R and U were quite similar and they seemed to have suitable pharmacokinetic properties for once a day dosage, and they showed a more sustained action than T. Only minimal gastrointestinal side effects were reported during this study.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3997302

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  3 in total

1.  Nocturnal oxygen saturation and body movement in asthmatics treated with controlled-release preparations of theophylline or terbutaline.

Authors:  P E Brander; A R Sovijärvi; T Salmi; A Hakulinen; H Poppius
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Once-daily theophylline in the treatment of nocturnal asthma.

Authors:  V Vilkka; P Brander; A Hakulinen; J Laitinen; K Sahlström; E Aalto; M Silvasti; P Karttunen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Nocturnal oxygen saturation and sleep quality in patients with advanced chronic obstructive pulmonary disease during treatment with moderate dose CR-theophylline.

Authors:  P E Brander; T Salmi
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.